ETF Flows Summary: Direxion Daily Pharmctcl&Medcl Bl 2X ETF (PILL) Declines 4.05% for Nov 23

November 23, 2016 - By Hazel Jackson   ·   0 Comments

Nov 23 is a negative day so far for Direxion Daily Pharmctcl&Medcl Bl 2X ETF (NYSEARCA:PILL) as the ETF is active during the day after losing 4.05% to hit $21.68 per share. The exchange traded fund has 2.91M net assets and 1.07% volatility this month.

Over the course of the day 500 shares traded hands, as compared to an average volume of 830 over the last 30 days for Direxion Daily Pharmctcl&Medcl Bl 2X ETF (NYSEARCA:PILL).

The ETF is -34.65% of its 52-Week High and 16.24% of its low, and is currently having ATR of 0.63. This year’s performance is -32.16% while this quarter’s performance is -21.10%.

The ETF’s YTD performance is -37.42%, the 1 year is -33.27% and the 3 year is NaN%.

The fund’s top holdings are: Dynamic Pharmaceutical Intellidex USD for 197.90% of assets, Fidelity Institutional Go for 41.19%.

More notable recent Direxion Daily Pharmaceutical & Medical Bull 2X Shares (NYSEARCA:PILL) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on September 22, 2015, also Etftrends.com with their article: “Direxion Debuts Double Leveraged Cyber Security, Pharmaceuticals ETFs” published on September 16, 2015, Marketwatch.com published: “Mr. Trump Goes To Washington” on November 15, 2016. More interesting news about Direxion Daily Pharmaceutical & Medical Bull 2X Shares (NYSEARCA:PILL) were released by: Etfdb.com and their article: “Saudi Arabian ETF Release; Direxion Launches Four ETFs” published on September 24, 2015 as well as Etfdailynews.com‘s news article titled: “ETF Stats For September 2015; Assets Back Below $2 Trillion” with publication date: October 09, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>